How does relugolix monotherapy affect bone mineral density (BMD)?

Label:chem

Topic
Estrogen suppression by GnRH antagonists can cause hypoestrogenic side effects, notably accelerated bone loss and increased osteoporosis risk.
Answer
Clinical trials show that 12 weeks of relugolix 40 mg once-daily monotherapy produces significant BMD loss (lumbar spine −2.2 %, total hip −1.4 %), reflecting the potent estrogen-suppressing effect that undermines bone homeostasis.
Return to Home Chemical List
Knowledge you may be interested in
What is relugolix, and how does it function as a therapeutic agent in uterine diseases? Does combining diazepam with low-frequency rTMS produce additive or synergistic suppression of Ca²⁺ elevation? What is diazepam’s pharmacological role in modulating epileptiform activity, and at what concentration was it tested? What is ferric derisomaltose (FDI), and what is its chemical role in research study? What are the molecular mechanisms by which vitamin D affects muscle health? How does vitamin D deficiency contribute to sarcopenia? What is the role of vitamin D (Vit D) in skeletal muscle physiology? What is the role of CBG (cannabigerol) in bone healing? What are the effects of THC (tetrahydrocannabinol) on bone healing? What is the effect of CBD (cannabidiol) on bone healing? What strategy has been developed to mitigate relugolix-induced BMD loss? Does relugolix combination therapy preserve BMD over extended treatment periods? How do clinical outcomes compare between relugolix monotherapy and combination therapy? What evidence supports the efficacy of relugolix combination therapy in endometriosis? What role does desloratadine or levocetirizine play when added to oral isotretinoin in the treatment of acne vulgaris? How do zinc ions affect influenza A virus (IAV) hemagglutinin function and virus infectivity? Does zinc-mediated inactivation compromise the structural integrity of the IAV particle? Is the antiviral activity of zinc ions maintained across physiologically relevant temperatures? What is Cucurbitacin E (CuE) and where is it derived from? Does Cucurbitacin E (CuE) exhibit cytotoxicity toward 3T3-L1 adipocytes during adipogenesis?